Cholesterylestertransferprotein (CETP) has been identified as a potential target for cardiovascular disease (CVD) for its important role in the reverse cholesteryltransfer (RCT) process. In our previous work, compound 5 was discovered as a moderate CETPinhibitor. The replacement of the amide linker by heterocyclic aromatics and then a series of N,N-substituted-4-arylthiazole-2-methylamine derivatives